Abbott Laboratories (NYSE:ABT) Given New $112.00 Price Target at Wells Fargo & Company

Abbott Laboratories (NYSE:ABT) had its target price hoisted by Wells Fargo & Company from $109.00 to $112.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has an “overweight” rating on the healthcare product maker’s stock. Wells Fargo & Company‘s target price points to a potential upside of 10.51% from the company’s current price.

ABT has been the topic of several other reports. Royal Bank Of Canada reissued an “outperform” rating and set a $130.00 price target on shares of Abbott Laboratories in a research report on Friday. Barclays decreased their price objective on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research report on Monday, April 20th. Sanford C. Bernstein dropped their target price on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Jefferies Financial Group cut their target price on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Finally, Leerink Partners lowered their price target on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a report on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $117.87.

Abbott Laboratories Trading Up 2.6%

Abbott Laboratories stock traded up $2.52 during midday trading on Friday, reaching $101.35. The stock had a trading volume of 5,051,196 shares, compared to its average volume of 12,286,831. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The firm has a market cap of $176.54 billion, a price-to-earnings ratio of 28.39, a PEG ratio of 1.54 and a beta of 0.61. The firm’s fifty day simple moving average is $89.56 and its two-hundred day simple moving average is $102.18.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. The company had revenue of $12.51 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company’s revenue was up 13.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Philip P. Boudreau bought 2,200 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The shares were acquired at an average price of $91.50 per share, with a total value of $201,300.00. Following the purchase, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ABT. MidAtlantic Capital Management Inc. bought a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $25,000. Cornerstone Financial Management LLC bought a new position in Abbott Laboratories during the fourth quarter worth $25,000. Purpose Unlimited Inc. acquired a new position in Abbott Laboratories during the 4th quarter valued at $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in Abbott Laboratories during the 4th quarter valued at $26,000. Finally, Abound Financial LLC bought a new stake in Abbott Laboratories in the 4th quarter valued at $26,000. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott reported Q2 adjusted EPS of $1.31, edging past estimates, while revenue rose 13% year over year to $12.51 billion, signaling broad underlying demand. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: The company lifted its 2026 adjusted EPS guidance to $5.45-$5.60 and kept its comparable sales outlook intact, which investors read as a sign of confidence in second-half momentum. Abbott raises 2026 profit forecast on heart device strength
• Positive Sentiment: Growth in medical devices and diagnostics, especially stronger demand for heart devices, helped offset softer areas and supported the upbeat guidance update. Abbott Stock’s Best Day Ever: +13.6% On Earnings Beat, Guidance Raise
• Positive Sentiment: BTIG Research raised its price target to $134 from $131 and reiterated a Buy rating, implying meaningful upside from current levels and adding to the bullish post-earnings sentiment. Benzinga analyst update
• Neutral Sentiment: Several market commentaries highlighted that ABT had been viewed as undervalued or recovering from a prior decline, but these were mostly opinion pieces rather than new fundamentals. Is Abbott Laboratories (ABT) Below Fair Value After Its 31% Fall?

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.